総合代謝パネル検査の世界市場

総合代謝パネル検査の世界市場は2030年までに181億米ドルに達する

2024年に115億米ドルと推定される総合代謝パネル検査の世界市場は、2024年から2030年にかけてCAGR 7.8%で成長し、2030年には181億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるグルコースは、CAGR 9.7%を記録し、分析期間終了時には37億米ドルに達すると予測されます。クレアチニン・セグメントの成長率は、分析期間でCAGR 8.4％と推定されます。

米国市場は31億米ドルと推定される一方、中国はCAGR 12.4％で成長すると予測される

米国の総合代謝パネル検査市場は2024年に31億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに39億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.4%です。その他の注目すべき地域別市場としては日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.6%と予測されています。欧州では、ドイツがCAGR 5.2%で成長すると予測されています。

世界の総合代謝パネル検査市場- 主要動向と促進要因のまとめ

なぜ総合代謝パネル検査の重要性が高まっているのか？

総合代謝パネル検査は、全体的な代謝機能、臓器の健康状態、電解質バランスに関する貴重な洞察を提供する、現代のヘルスケアにおける重要なツールとなっています。グルコースレベル、腎機能、肝酵素、電解質不均衡を測定するこの血液検査は、日常健康診断、慢性疾患管理、術前評価に広く使用されています。代謝異常、腎臓病、肝臓疾患の有病率の上昇に伴い、CMP検査の需要は病院、診断研究所、外来診療所全体で着実に増加しています。糖尿病と心血管疾患の世界の負担増は、CMP検査採用の主要な推進力となっています。代謝異常の早期発見により、医療従事者は糖尿病、高血圧、腎機能障害などの病態が重篤な合併症に進展する前に診断・管理することができます。さらに、高齢者人口の増加に伴い、定期的な代謝評価の必要性が高まっています。高齢者は、継続的なモニタリングを必要とする複数の慢性疾患のリスクが高いためです。CMP検査の需要を促進するもう一つの重要な要因は、世界の予防ヘルスケア・イニシアチブの拡大です。政府やヘルスケア機関は、非伝染性疾患の発生率を低下させるため、定期的な健康診断を積極的に推進しています。企業のウェルネス・プログラムや健康保険プロバイダーも、定期的な血液検査を奨励し、CMP検査量の増加につながっています。ヘルスケア・システムが反応的アプローチから予防的アプローチに移行する中、包括的代謝パネルは、患者の積極的ケアにおいて重要な役割を果たしています。

技術の進歩は、CMP検査の精度と効率をどのように高めていますか？

診断技術の進化により、総合代謝パネル検査の精度、スピード、アクセシビリティは著しく向上しています。生化学自動分析装置の導入は臨床検査室に革命をもたらし、最小限の人的介入でより迅速かつ正確な検査を可能にしました。このような進歩により、所要時間が短縮され、迅速な診断と治療方針の決定が可能となりました。さらに、試薬の処方とアッセイの標準化が改善されたことで、代謝パネルの結果の信頼性が向上し、診断精度がより確実になりました。ポイント・オブ・ケア検査（POCT）もまた、CMP検査の状況を一変させる大きな技術開発です。ポータブルでハンドヘルドの生化学分析装置により、救急外来、外来診療所、さらには在宅環境でも、その場で代謝評価ができるようになりました。従来の検査インフラを必要とせずに迅速な結果が得られるようになったことで、患者の利便性が向上し、臨床ワークフローが合理化されました。診断検査室における人工知能（AI）と機械学習の統合は、CMP検査の効率をさらに最適化しています。AIを搭載したデータ分析プラットフォームは、動向の特定、異常結果のフラグ付け、代謝の健康状態に関する予測的洞察の提供に利用されています。これらの技術は、医師による疾患の早期発見とリスク評価を支援し、患者の転帰を改善しています。さらに、電子カルテ（EHR）による検査結果のデジタル化は、データへのアクセス性を高め、代謝状態の管理における患者と医療者のより良い連携を可能にしています。

CMP検査の成長を促す市場動向とは？

総合代謝パネル検査市場を形成する最も注目すべき動向の1つは、在宅診断ソリューションの採用が増加していることです。消費者直販（DTC）検査サービスの台頭により、医師の紹介を必要とせずにCMP検査を注文することで、個人が自分の健康を管理できるようになりました。オンライン・ヘルス・プラットフォームや遠隔医療プロバイダーは、在宅採血キットを提供しており、ユーザーは検査室での分析用にサンプルを提出し、デジタル結果を受け取ることができます。この動向は、利便性と予防ヘルスケアを優先するテクノロジーに精通した消費者の間で特に支持を集めています。診断ラボのネットワークと戦略的パートナーシップの拡大も市場成長を後押ししています。大手診断サービス・プロバイダーは、新たな検査施設を開設したり、病院や診療所と提携を結んだりして、その足跡を拡大しています。こうした提携により、特にこれまで高度な診断サービスが制限されていた医療未整備地域において、CMP検査への幅広いアクセスが確保されつつあります。さらに、多国籍診断企業は、新興国市場におけるメタボリックスクリーニングの需要の高まりを認識し、新興国市場に投資しています。検査施設の品質基準と検査償還政策を改善するための規制当局の取り組みは、市場力学をさらに形成しています。多くの国が生化学検査の正確性と信頼性を確保するために厳格なガイドラインを導入しており、診断サービスに対する信頼を醸成しています。同時に、CMPを含む日常的な血液検査に対する医療保険の適用範囲がいくつかの地域で改善されつつあり、これらの検査がより手頃な価格で、より多くの患者集団が利用できるようになっています。ヘルスケアの支払者が病気の早期発見によるコスト削減効果を認識するにつれて、予防的代謝スクリーニングの保険適用方針は拡大すると予想されます。

市場を促進する主な成長要因は何か？

総合代謝パネル検査市場の成長は、診断自動化の進展、慢性疾患有病率の増加、ポイントオブケア検査ソリューションの拡大など、いくつかの要因によってもたらされます。主な成長要因の一つは、代謝性疾患、特に糖尿病、肥満、腎臓病の罹患率の上昇です。これらの疾患が広まるにつれて、定期的な代謝評価が疾患のモニタリングと管理に不可欠となり、検査量の増加につながっています。デジタル・ヘルス・ソリューションの採用が増加していることも、市場拡大に寄与する主な要因です。遠隔医療プラットフォームは、CMP検査をバーチャル・ケア・モデルに統合することで、遠隔患者モニタリングを可能にし、慢性疾患管理を強化しています。デジタルヘルス企業は検査施設と提携し、シームレスなオンライン検査注文と結果配信を提供することで、代謝パネル検査をより便利で利用しやすいものにしています。診断学とデジタルヘルスの融合により、臨床と在宅の両環境におけるCMP検査の継続的な普及が期待されます。新興国におけるヘルスケア・インフラの拡充も、市場成長に重要な役割を果たしています。新興諸国では、診断ラボや病院施設への投資が増加し、定期的な健康診断へのアクセスが向上しています。これらの地域の政府は、疾病の早期発見を促進するための公衆衛生イニシアチブを打ち出しており、CMP検査の需要をさらに押し上げています。さらに、新興市場における可処分所得の増加と健康意識の高まりが、予防的ヘルスケアサービスを求める個人の行動を促し、市場全体の拡大に寄与しています。さらに、メタボリックパネル検査におけるバイオマーカー検出の強化を目指した研究開発が進行しており、新たな成長機会の開拓が期待されています。科学者たちは、代謝の健康状態についてより深い洞察を提供し、より正確なリスク評価と個別化された治療計画を可能にする新規バイオマーカーを探求しています。診断機能が進化し続ける中、総合代謝パネル検査市場は、技術革新、ヘルスケアアクセスの拡大、予防医学の重視の高まりに牽引され、持続的な成長が見込まれています。

セグメント

分析項目（グルコース、クレアチニン、Ca++、ALT、BUN、K+、総タンパク質、総ビリルビン、その他分析項目）;疾患（腎臓病、糖尿病、肝臓病、その他疾患）;エンド・ユース（検査室エンド・ユース、PoCエンド・ユース）

調査対象企業の例

• Abbott Laboratories
• American Esoteric Laboratories
• ARUP Laboratories
• Baptist Health Medical Group
• CENTOGENE N.V.
• Charles River Laboratories Inc.
• Genoptix Inc.
• LabCorp Drug Development
• Laboratory Corporation of America Holdings（LabCorp）
• Laboratory Services of America
• NeoGenomics Laboratories, Inc.
• Nova Medical
• Quest Diagnostics
• Scion Lab Services LLC
• Siemens Healthcare GmbH
• Sonic Healthcare
• SYNLAB International GmbH
• TCG Corp.
• UNIPATH
• Walk-In Lab, LLC

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Comprehensive Metabolic Panel Testing Market to Reach US$18.1 Billion by 2030

The global market for Comprehensive Metabolic Panel Testing estimated at US$11.5 Billion in the year 2024, is expected to reach US$18.1 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Glucose, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Creatinine segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 12.4% CAGR

The Comprehensive Metabolic Panel Testing market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Comprehensive Metabolic Panel Testing Market - Key Trends & Drivers Summarized

Why Is Comprehensive Metabolic Panel Testing Becoming Increasingly Important?

Comprehensive metabolic panel testing has become a critical tool in modern healthcare, providing valuable insights into overall metabolic function, organ health, and electrolyte balance. This blood test, which measures glucose levels, kidney function, liver enzymes, and electrolyte imbalances, is widely used for routine health check-ups, chronic disease management, and preoperative assessments. With the rising prevalence of metabolic disorders, kidney diseases, and liver conditions, the demand for CMP testing is steadily increasing across hospitals, diagnostic laboratories, and outpatient clinics. The growing global burden of diabetes and cardiovascular diseases has been a major driver for CMP testing adoption. Early detection of metabolic abnormalities allows healthcare providers to diagnose and manage conditions such as diabetes mellitus, hypertension, and kidney dysfunction before they progress into severe complications. Additionally, with the increasing geriatric population, the need for regular metabolic assessments has risen, as older individuals are at higher risk for multiple chronic conditions that require continuous monitoring. Another significant factor driving CMP testing demand is the expansion of preventive healthcare initiatives worldwide. Governments and healthcare organizations are actively promoting regular health screenings to reduce the incidence of non-communicable diseases. Corporate wellness programs and health insurance providers are also incentivizing routine blood tests, leading to an increase in CMP testing volumes. As healthcare systems shift from reactive to preventive approaches, comprehensive metabolic panels are playing a crucial role in proactive patient care.

How Are Technological Advancements Enhancing the Accuracy and Efficiency of CMP Testing?

The evolution of diagnostic technologies has significantly improved the accuracy, speed, and accessibility of comprehensive metabolic panel testing. The introduction of automated biochemical analyzers has revolutionized clinical laboratories, enabling faster and more precise testing with minimal human intervention. These advancements have reduced turnaround times, allowing for quicker diagnosis and treatment decisions. Additionally, improvements in reagent formulations and assay standardization have enhanced the reliability of metabolic panel results, ensuring greater diagnostic accuracy. Point-of-care testing (POCT) is another major technological development that is transforming the CMP testing landscape. Portable and handheld biochemical analyzers now allow for on-the-spot metabolic assessments in emergency rooms, outpatient clinics, and even home settings. The ability to obtain rapid results without requiring traditional laboratory infrastructure has improved patient convenience and streamlined clinical workflows, particularly in critical care scenarios where timely intervention is crucial. The integration of artificial intelligence (AI) and machine learning in diagnostic laboratories is further optimizing CMP testing efficiency. AI-powered data analytics platforms are being used to identify trends, flag abnormal results, and provide predictive insights into metabolic health. These technologies are aiding physicians in early disease detection and risk assessment, improving patient outcomes. Moreover, the digitization of lab results through electronic health records (EHR) is enhancing data accessibility and enabling better patient-provider collaboration in managing metabolic conditions.

What Market Trends Are Driving the Growth of CMP Testing?

One of the most notable trends shaping the comprehensive metabolic panel testing market is the increasing adoption of at-home diagnostic solutions. The rise of direct-to-consumer (DTC) testing services has empowered individuals to take charge of their health by ordering CMP tests without the need for physician referrals. Online health platforms and telemedicine providers are offering home-based blood collection kits, allowing users to submit samples for laboratory analysis and receive digital results. This trend is particularly gaining traction among tech-savvy consumers who prioritize convenience and preventive healthcare. The expansion of diagnostic laboratory networks and strategic partnerships is also fueling market growth. Leading diagnostic service providers are expanding their footprints by opening new testing facilities and forming collaborations with hospitals and clinics. These partnerships are ensuring wider accessibility to CMP testing, particularly in underserved regions where advanced diagnostic services were previously limited. Additionally, multinational diagnostic companies are investing in emerging markets, recognizing the growing demand for metabolic screening in developing countries. Regulatory efforts to improve laboratory quality standards and test reimbursement policies are further shaping market dynamics. Many countries are implementing stringent guidelines to ensure the accuracy and reliability of biochemical testing, fostering trust in diagnostic services. At the same time, health insurance coverage for routine blood tests, including CMPs, is improving in several regions, making these tests more affordable and accessible to a larger patient population. As healthcare payers recognize the cost-saving benefits of early disease detection, coverage policies for preventive metabolic screening are expected to expand.

What Are the Key Growth Drivers Fueling the Market?

The growth in the comprehensive metabolic panel testing market is driven by several factors, including advancements in diagnostic automation, increasing chronic disease prevalence, and the expansion of point-of-care testing solutions. One of the primary growth drivers is the rising incidence of metabolic disorders, particularly diabetes, obesity, and kidney disease. As these conditions become more widespread, regular metabolic assessments are becoming essential for disease monitoring and management, leading to higher testing volumes. The increasing adoption of digital health solutions is another major factor contributing to market expansion. Telemedicine platforms are integrating CMP testing into virtual care models, enabling remote patient monitoring and enhancing chronic disease management. Digital health companies are partnering with laboratories to offer seamless online test ordering and result delivery, making metabolic panel testing more convenient and accessible. The convergence of diagnostics and digital health is expected to drive continued adoption of CMP testing in both clinical and home settings. The expansion of healthcare infrastructure in emerging economies is also playing a crucial role in market growth. Developing countries are witnessing increased investments in diagnostic laboratories and hospital facilities, improving access to routine health screenings. Governments in these regions are launching public health initiatives to promote early disease detection, further driving demand for CMP testing. Additionally, the rising disposable incomes and growing health consciousness in emerging markets are encouraging individuals to seek preventive healthcare services, contributing to the overall market expansion. Furthermore, ongoing research and development efforts aimed at enhancing biomarker detection in metabolic panel testing are expected to open new growth opportunities. Scientists are exploring novel biomarkers that can provide deeper insights into metabolic health, enabling more precise risk assessment and personalized treatment plans. As diagnostic capabilities continue to evolve, the comprehensive metabolic panel testing market is poised for sustained growth, driven by technological innovation, expanding healthcare access, and the increasing emphasis on preventive medicine.

SCOPE OF STUDY:

The report analyzes the Comprehensive Metabolic Panel Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Analytes (Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin, Other Analytes); Disease (Kidney Diseases, Diabetes, Liver Diseases, Other Diseases); End-Use (Laboratories End-Use, PoC End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• American Esoteric Laboratories
• ARUP Laboratories
• Baptist Health Medical Group
• CENTOGENE N.V.
• Charles River Laboratories Inc.
• Genoptix Inc.
• LabCorp Drug Development
• Laboratory Corporation of America Holdings (LabCorp)
• Laboratory Services of America
• NeoGenomics Laboratories, Inc.
• Nova Medical
• Quest Diagnostics
• Scion Lab Services LLC
• Siemens Healthcare GmbH
• Sonic Healthcare
• SYNLAB International GmbH
• TCG Corp.
• UNIPATH
• Walk-In Lab, LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Comprehensive Metabolic Panel Testing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Focus on Preventive Healthcare and Routine Screening Drives Demand for Metabolic Panel Testing
  • Expansion of Wellness Programs and Annual Health Check-Ups Fuels Clinical Adoption
  • OEM Integration With Lab Information Systems and EHR Enhances Test Ordering and Reporting Efficiency
  • Growing Use in Chronic Disease Management Programs Supports Repeat and Panelized Testing
  • Increased Use in Preoperative Evaluations and Baseline Assessments Enhances Test Frequency
  • OEM Development of Automated and High-Throughput Analyzers Supports Laboratory Efficiency
  • Growing Role of Telemedicine and At-Home Sample Collection Expands Access to Testing
  • OEMs Offering Multiplexed Assays and Expanded Biomarker Panels Improve Diagnostic Value
  • Rising Utilization in Monitoring Liver, Kidney, and Electrolyte Function Across Age Groups Broadens Application
  • OEMs Supporting Customizable Panel Configurations Enable Use in Specialized Clinical Settings
  • Growth in Corporate Wellness and Occupational Health Screening Programs Drives Institutional Demand
  • OEM Collaborations With Diagnostic Labs and Clinics Expand Geographic and Segment Reach
  • Increased Insurance Coverage and Employer Reimbursement Models Encourage Test Utilization
  • OEMs Offering Integration With Decision Support Tools Improve Interpretation and Clinical Actionability
  • Rise in Point-of-Care Testing and Rapid Diagnostic Platforms Enhances Speed of Diagnosis
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Comprehensive Metabolic Panel Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Glucose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Glucose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Glucose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Creatinine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Creatinine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Creatinine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Ca++ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Ca++ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Ca++ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for ALT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for ALT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for ALT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for BUN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for BUN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for BUN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for K+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for K+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for K+ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Total Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Total Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Total Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Total Bilirubin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Total Bilirubin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Total Bilirubin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Analytes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Analytes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Analytes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Kidney Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Kidney Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Kidney Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for PoC End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for PoC End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for PoC End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION